Cytokinetics (CYTK) Other Non-Current Liabilities (2016 - 2026)

Cytokinetics (CYTK) has reported Other Non-Current Liabilities for 10 consecutive years, with $29.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 152.99% year-over-year to $29.6 million; the TTM figure through Mar 2026 stood at $29.6 million (up 152.99% YoY), while the FY2025 annual figure was $31.1 million, up 175.22% from the prior year.
• Other Non-Current Liabilities slipped to $29.6 million in Q1 2026 per CYTK's latest filing, from $31.1 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $104.7 million in Q2 2024 and bottomed at $408000.0 in Q3 2023.
• Historically, Other Non-Current Liabilities has averaged $14.8 million across 5 years, with a median of $7.3 million in 2022.
• Annual changes were most pronounced in 2022 — Other Non-Current Liabilities plunged 99.29% — and 2024, when it jumped 16652.0%.
• Cytokinetics' Other Non-Current Liabilities stood at $1.0 million in 2022, then surged by 1106.9% to $12.6 million in 2023, then decreased by 10.32% to $11.3 million in 2024, then surged by 175.22% to $31.1 million in 2025, then declined by 4.82% to $29.6 million in 2026.
• Business Quant data shows CYTK's Other Non-Current Liabilities at $29.6 million in Q1 2026, $31.1 million in Q4 2025, and $1.6 million in Q3 2025.